The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Paroxetine versus Clomipramine in the Treatment of Obsessive–Compulsive Disorder
Abstract
Background: The aim was to assess the effect of a flexible dose of paroxetine, compared with clomipramine and placebo, in obsessive-compulsive disorder (OCD). Method: In a multinational randomised study, 406 subjects with OCD of at least six months duration received double-blind mediation for up to 12 weeks. Doses were adjusted according to therapeutic effect and side-effects. Primary efficacy measures were the Yale–Brown Obsessive–Compulsive Scale and the National Institute of Mental Health Obsessive–Compulsive Scale. Secondary efficacy measures were the Montgomery–åsberg Depression Rating Scale, Symptom Check-List (90), Clinical Global Impression, and Patients' Global Evaluation. Results: Paroxetine was significantly more effective than placebo, and of comparable efficacy to clomipramine. Paroxetine had significantly superior tolerability to clomipramine on three measures: CGI efficacy index, anticholinergic adverse events, and adverse events leading to withdrawal. Conclusion: Paroxetine is as effective as clomipramine in the treatment of OCD. The comparable efficacy and better tolerability of paroxetine suggest that it would be an appropriate treatment for OCD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The Yale-Brown Obsessive-Compulsive Scale: Measures of internal consistency
Kim, S. W., Dysken, M. W., Pheley, A. M., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,359
The Epidemiology and Clinical Features of Obsessive Compulsive Disorder
Rasmussen, S. A., & Eisen, J. L. (1992) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30205-3 · Cited by 867
The Cross National Epidemiology of obsessive-compulsive disorder
Weisman, M. M., Bland, R. C., CANINO, G. J., Greenwald, S., Hwu, H., Lee, C. K., Newman, S. C., Browne, M. A. O., Rubio-Stipec, M., WICKRAMARATNE, P. J., et al. (1994) · Max Planck Institute for Plasma Physics · Cited by 688
Compulsive buying: descriptive characteristics and psychiatric comorbidity.
Ga, C., Faber, R., de Zwaan, M., Raymond, N. C., Sm, S., Ekern, Tb, M., Crosby, R. D., Sj, C., & Ed, E. (1994) · PubMed · Cited by 664
Greist, J. H. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950130053006 · Cited by 500
COMFORT, EFFECTIVENESS, AND SELF-AWARENESS AS CRITERIA OF IMPROVEMENT IN PSYCHOTHERAPY
PARLOFF, M. B., KELMAN, H. C., & FRANK, J. D. (1954) · American Journal of Psychiatry · doi:10.1176/ajp.111.5.343 · Cited by 459
Tollefson, G. D. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950070051010 · Cited by 314
Greist, J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160039008 · Cited by 243
Pigott, T. A. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220042005 · Cited by 221
A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients
Dunbar, G. C., Cohn, J. B., Fabre, L. F., Feighner, J. P., Fieve, R. R., Mendels, J., & Shrivastava, R. K. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.159.3.394 · Cited by 175
Montgomery, S. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90266-o · Cited by 172
Fluoxetine Treatment of Obsessive-Compulsive Disorder
TURNER, S. M., JACOB, R. G., BEIDEL, D. C., & HIMMELHOCH, J. (1985) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198508000-00003 · Cited by 167
McTavish, D., & Benfield, P. (1990) · Drugs · doi:10.2165/00003495-199039010-00010 · Cited by 161
The Dynamics of Complex Biological-Psychosocial Systems
Ciompi, L. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000295925 · Cited by 141
Chouinard, G., Goodman, W. K., Greist, J. H., Jenike, M. A., Rasmussen, S., White, K., Hackett, E., Gaffney, M., & Bick, P. A. (1990) · PubMed · Cited by 136
Freeman, C. P. L., Trimble, M., Deakin, J. F. W., Stokes, T., & Ashford, J. J. (1994) · PubMed · Cited by 125
Pharmacotherapy of Obsessive-Compulsive Disorder
Goodman, W. K. (1992) · Springer eBooks · doi:10.1007/978-3-642-77608-3_13 · Cited by 118
Obsessive—Compulsive Disorder as a 5-HT Subsystem-Related Behavioural Disorder
Murphy, D. L., Zohar, J., Benkelfat, C., Pato, M. T., Pigott, T. A., & Insel, T. R. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291721 · Cited by 108
Self-citationBiological Approaches to Treatment-Resistant Obsessive-Compulsive Disorder
Goodman, W. K., Rudorfer, M. V., & Maser, J. D. (2017) · Routledge eBooks · doi:10.4324/9781315561073-31 · Cited by 97
The Pharmacotherapy of Obsessive-Compulsive Disorder
McDougle, C. J., Goodman, W. K., & Price, L. H. (1993) · Pharmacopsychiatry · doi:10.1055/s-2007-1014373 · Cited by 86
A Multicenter Double-Blind Trial of Paroxetine Versus Amitriptyline in Depressed Inpatients
Stuppaeck, C., Geretsegger, C., Whitworth, A. B., SCHUBERT, H., Platz, T., NIG, P. K., Hinterhuber, H., & Fleischhacker, W. W. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199408000-00003 · Cited by 64
Fluoxetine in the treatment of obsessive compulsive disorder
Fontaine, R., & Chouinard, G. (1985) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(85)90025-9 · Cited by 55
An integrated approach to treatment of obsessive compulsive disorder.
Greist, J. H. (1992) · PubMed · Cited by 50
Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder
Fineberg, N. A., Bullock, T., Montgomery, D., & Montgomery, S. A. (1992) · International Clinical Psychopharmacology · doi:10.1097/00004850-199206001-00012 · Cited by 40
The effect of paroxetine on anxiety and agitation associated with depression.
Sheehan, D. V., Dunbar, G. C., & Dl, F. (1992) · PubMed · Cited by 39
Arminen, S.-L., Ikonen, U., Pulkkinen, P., Leinonen, E. V. J., Mahlanen, A., Koponen, H., Kourula, K., Ryyppö, J., Korpela, V., Lehtonen, M. L., et al. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01533.x · Cited by 30
Biological Approaches to Treatment-Resistant Obsessive-Compulsive Disorder
Goodman, W. K., Ward, H. E., Kablinger, A. S., & Murphy, T. K. (1999) · Routledge eBooks · doi:10.4324/9781410603241-23 · Cited by 29
Cited by
Grant, B. F., Chou, S. P., Goldstein, R. B., Huang, B., Stinson, F. S., Saha, T. D., Smith, S. M., Dawson, D. S., Pulay, A. J., Pickering, R. P., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0404 · Cited by 1,618
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Axis I Comorbidity of Borderline Personality Disorder
Zanarini, M. C., Frankenburg, F. R., Dubo, E. D., Sickel, A. E., Trikha, A., Levin, A., & Reynolds, V. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.12.1733 · Cited by 977
Stein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citation
Metadata
- Authors
- Zohar, J., Judge, R., & Ocd Paroxetine Study Investigators
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1996-10
- Volume
- 169
- Issue
- 4
- Pages
- 468-474
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2162253908
- Cited by
- 272
- References
- 29
- FWCI
- 18.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.